MS drug withdrawn following brain disorders

Biogen Australia is withdrawing Zinbryta (daclizumab) from the global and Australian market following cases of serious inflammatory brain disorders The TGA says it has not received any reports of inflammatory brain disorders occurring in Australian patients who have been prescribed Zinbryta. The cases of immune-mediated encephalitis and meningoencephalitis reported occurred in Europe. Biogen says it